BioCentury
ARTICLE | Distillery Techniques

Techniques: Patient-derived chordoma cell lines for therapeutic screening

September 24, 2015 7:00 AM UTC

Newly generated chordoma cell lines could be used to screen for therapies to treat the rare cancer. Eight new chordoma cell lines established from patient tumor samples recapitulated the markers and phenotypic properties of the parent tumor cells. Genomic and proteomic analysis showed all eight cell lines highly expressed activated forms of cyclin dependent kinase 4 (CDK4), CDK6 and retinoblastoma 1 (RB1). In the cell lines, the CDK4/CDK6 inhibitor Ibrance palbociclib reduced cell viability with IC50 values of 50-100 nM. Next steps could include using the cells to screen for additional therapies for chordoma.

Pfizer Inc. and Amgen Inc. market Ibrance to treat breast cancer. ...